Healthcare · NSE: MARKSANS
Marksans Pharma
Q2 FY27 earnings and concall highlights
Q2 FY27 earnings call · Guided by management
Call held 5 Nov 2026 · Read the filing on NSEFiling
- M.Cap
- ₹14,012Cr
- P/E
- 25.0×
- 1Y return
- +60.67%
- From 52W high
- −11.9%
Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.
Share price
Results Q2 FY27, as filed · consolidated · ₹ Cr
| Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ | |
|---|---|---|---|---|---|
| Revenue | 940 | 720 | +30.5% | 841 | +11.8% |
| EBITDA | 214 | 144 | +48.3% | 213 | +0.6% |
| EBITDA margin | 22.8% | 20.1% | +273 bps | 25.3% | -255 bps |
| PBTProfit before tax | 194 | 133 | +45.1% | 207 | -6.3% |
| Net profit | 141 | 98 | +43.8% | 157 | -10.1% |
| EPS (₹) | 3.11 | 2.17 | +43.3% | 3.47 | -10.4% |
From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.
Guidance
PAT expected in line with expectations, apart from tax and depreciation
Mark Saldanha · Chairman and Managing Director · Q&A · p. 8
PAT expected in line with expectations, apart from tax and depreciation
“The PAT, with regards to PAT, I think besides provisions for different taxes and depreciation, I think our PAT will be pretty much in line with what is expected.”
More figures from the call
“within the next couple of months, till March, we should be filing another five or six ANDAs.”
“I would probably put 12 months.”
“So far, we are good for the next two years, two to three years. But you always want additional capacity.”
“EBITDA increased year-on-year by 48.3% to INR214 crores, with EBITDA margin expanding by 274 basis points to 22.8%, ahead of our 20%-21% guidance range.”
In short
- 01Q2 revenue from operations was INR940 crore, up 30.5% year on year.
- 02Q2 EBITDA rose 48.3% to INR214 crore, at a 22.8% margin, above the 20%-21% guidance range.
- 03Management expects EBITDA margin of about 21%-22% for the year and gross margin of 55%-56%.
- 04Management expects revenue of INR4,000 crore next year, INR5,000 crore in three years and about INR6,000 crore in five years.
- 05U.S. order book is expected to grow from $225 million to $300 million within three years.
- 06Capacity expansion is planned through new blocks at the Teva plant or buying a plant; talks are on with two companies.
- 07More European acquisitions are hoped for within 12 months; net cash stood at INR1,095 crore.
- 08Freight costs nearly doubled and inventory costs rose; Rest of World shipments were hit by geopolitical disruption.
Capex
Capex planned: new manufacturing block or plant acquisition; talks on both
Mark Saldanha · Chairman and Managing Director · p. 7
Capex planned: new manufacturing block or plant acquisition; talks on both
“It may be adding on another manufacturing block or acquiring another plant. We are in active dialogue on both sides.”
India: Looking to acquire facilities in India, needing a decent amount of cash
Mark Saldanha · Chairman and Managing Director · p. 10
India: Looking to acquire facilities in India, needing a decent amount of cash
“But till then, we are now looking at acquiring facilities in India, for which we would probably need a decent amount of cash to be plowed out there on those fronts.”
Revenue targets will need capex in manufacturing infrastructure
Mark Saldanha · Chairman and Managing Director · p. 7
Revenue targets will need capex in manufacturing infrastructure
“We are working towards that, and that would need, obviously, infusion of capex in terms of manufacturing infrastructure to support that growth phase.”
Capacity
India: Plan to add a couple of blocks at the Teva plant for dosage forms and capacity
Mark Saldanha · Chairman and Managing Director · p. 9
India: Plan to add a couple of blocks at the Teva plant for dosage forms and capacity
“within our infrastructure that we have within the Teva plant, we are planning to add in a couple of blocks to expand dosage forms as well as some capacity, debottlenecking.”
Expanding dosage forms where capacity constraints seen in about two years; no injectables
Mark Saldanha · Chairman and Managing Director · p. 12
Expanding dosage forms where capacity constraints seen in about two years; no injectables
“we are looking at expanding dosage forms where we believe we foresee some constraints in terms of capacity, maybe two years down the line.”
Any new dosage-form plant will include a solid oral block
Mark Saldanha · Chairman and Managing Director · p. 18
Any new dosage-form plant will include a solid oral block
“But irrespective, whatever dosage forms we do get into, we will always ensure there is a solid oral block in and around that place.”
Segments
U.K. and Europe: U.K. and Europe revenue up 65% to about INR405 crore
Mark Saldanha · Chairman and Managing Director · p. 3
U.K. and Europe: U.K. and Europe revenue up 65% to about INR405 crore
“Revenue from this region increased by 65% to approximately INR405 crores.”
U.K. and Europe: U.K. and Europe grew 49% in Q2 excluding acquisitions
Mark Saldanha · Chairman and Managing Director · p. 4
U.K. and Europe: U.K. and Europe grew 49% in Q2 excluding acquisitions
“Even excluding the contribution from the acquisitions, our business in the region grew by 49% in Q2.”
North America: North America revenue INR421 crore, up 8.7% year on year
Mark Saldanha · Chairman and Managing Director · p. 4
North America: North America revenue INR421 crore, up 8.7% year on year
“we recorded our highest ever quarterly revenue of INR421 crores, representing a growth of 8.7% year-on-year.”
Australia and New Zealand: Australia and New Zealand revenue up 64% to about INR101 crore
Mark Saldanha · Chairman and Managing Director · p. 4
Australia and New Zealand: Australia and New Zealand revenue up 64% to about INR101 crore
“In Australia and New Zealand, revenue grew by 64% to approximately INR101 crores.”
U.K. and Europe: U.K. and Europe expected to keep growing over next couple of years
Mark Saldanha · Chairman and Managing Director · p. 8
U.K. and Europe: U.K. and Europe expected to keep growing over next couple of years
“If you ask me my outlook of U.K. and Europe, they will still continue to grow over the next couple of years and will be very important geographies to hit our objectives of INR6,000 crores.”
Demand
U.S.: Order book described as healthy and still building
Mark Saldanha · Chairman and Managing Director · p. 4
U.S.: Order book described as healthy and still building
“Our order book remains healthy and continues to build”
Most of H1 revenue growth of 32.9% came from volume
Jitendra Sharma · Chief Financial Officer · p. 10
Most of H1 revenue growth of 32.9% came from volume
“our entire growth, if you see the first half of the current year, our revenue has grown by 32.9%, and a substantial part of this has come through volume growth only.”
Third quarter is normally the stronger quarter
Mark Saldanha · Chairman and Managing Director · p. 10
Third quarter is normally the stronger quarter
“But the third quarter is normally the stronger quarter for us.”
Portfolio is seasonal, tilted towards the cold season
Mark Saldanha · Chairman and Managing Director · p. 6
Portfolio is seasonal, tilted towards the cold season
“A substantial amount of our portfolio is seasonal, which is obviously tilted more towards the cold season.”
U.S.: Rising U.S. living costs make medicines a low priority for consumers
Mark Saldanha · Chairman and Managing Director · p. 7
U.S.: Rising U.S. living costs make medicines a low priority for consumers
“Obviously, with costs going up, I think medicines are literally the last priority on everyone's mind.”
Margins and costs
Q2 EBITDA up 48.3% to INR214 crore; margin up 274 bps to 22.8%
Mark Saldanha · Chairman and Managing Director · p. 3
Q2 EBITDA up 48.3% to INR214 crore; margin up 274 bps to 22.8%
“EBITDA increased by 48.3% to INR214 crores, and our EBITDA margin expanded by 274 basis points to 22.8%.”
Higher inventory costs moved gross margin to 58.5% from 59.1% in Q1
Jitendra Sharma · Chief Financial Officer · p. 5
Higher inventory costs moved gross margin to 58.5% from 59.1% in Q1
“However, we are now seeing an increase in inventory costs, resulting in gross margin moving to 58.5% from 59.1% in the previous quarter.”
Freight costs nearly doubled, adding about INR20 crore to other expenses
Jitendra Sharma · Chief Financial Officer · p. 5
Freight costs nearly doubled, adding about INR20 crore to other expenses
“Notably, freight costs have nearly doubled in the current environment. Higher freight contributed approximately INR20 crores to the sequential increase in other expenses.”
Employee costs rose about INR8 crore to build team for newer markets
Jitendra Sharma · Chief Financial Officer · p. 5
Employee costs rose about INR8 crore to build team for newer markets
“There has also been a slight increase in employee costs, of approximately INR8 crores, as we continue to strengthen our team and invest in the newer markets.”
Lower other income and effective tax rate of 25.8% in Q2
Jitendra Sharma · Chief Financial Officer · p. 6
Lower other income and effective tax rate of 25.8% in Q2
“related intangible assets, lower other income as currency movements stabilized, and a higher effective tax rate of 25.8%.”
Debt and working capital
H1 cash from operations INR322 crore versus INR75 crore a year ago
Jitendra Sharma · Chief Financial Officer · p. 6
H1 cash from operations INR322 crore versus INR75 crore a year ago
“Cash generated from operations was INR322 crores compared with INR75 crores in the corresponding period last year.”
Working capital cycle cut to about 128 days from 138 days in FY26
Jitendra Sharma · Chief Financial Officer · p. 6
Working capital cycle cut to about 128 days from 138 days in FY26
“The working capital cycle reduced to approximately 128 days in the first half of the year from 138 days in FY 2026.”
Net cash INR1,095 crore; net worth INR3,367 crore
Jitendra Sharma · Chief Financial Officer · p. 6
Net cash INR1,095 crore; net worth INR3,367 crore
“Our net cash position was therefore at INR1,095 crores, while net worth stood at INR3,367 crores.”
U.K.: Rise in lease liabilities came from a new lease in the U.K.
Jitendra Sharma · Chief Financial Officer · Q&A · p. 16
U.K.: Rise in lease liabilities came from a new lease in the U.K.
“Yes, we have taken a new lease in U.K., and it has come from that geography.”
H1 cash conversion (operating cash flow / EBITDA) 75.2% from 30.7%
Jitendra Sharma · Chief Financial Officer · p. 6
H1 cash conversion (operating cash flow / EBITDA) 75.2% from 30.7%
“Cash conversion, measured as operating cash flow as a percentage of EBITDA, improved to 75.2% from 30.7%.”
Acquisitions and new business
Europe: QliniQ (Netherlands) contributed about INR84 crore in H1
Mark Saldanha · Chairman and Managing Director · p. 4
Europe: QliniQ (Netherlands) contributed about INR84 crore in H1
“QliniQ in the Netherlands contributed approximately INR84 crores for the first half, while ABCnow and Marksans GmbH are strengthening our platform in Germany.”
H1 outflows: about INR95 crore on acquisitions, INR41 crore dividend
Jitendra Sharma · Chief Financial Officer · p. 6
H1 outflows: about INR95 crore on acquisitions, INR41 crore dividend
“During H1, we deployed around INR95 crores towards acquisitions and paid a dividend of around INR41 crores.”
Europe: Hopes to conclude a couple of European acquisitions within 12 months
Mark Saldanha · Chairman and Managing Director · p. 9
Europe: Hopes to conclude a couple of European acquisitions within 12 months
“Then we are looking at and exploring more M&As in Europe, and we do hope to conclude a couple of them down the line, hopefully within the next 12 months.”
India: In talks with two companies on plant acquisition, nothing concrete yet
Mark Saldanha · Chairman and Managing Director · p. 9
India: In talks with two companies on plant acquisition, nothing concrete yet
“We are basically in dialogue with two companies today, but nothing concrete.”
Middle East: No acquisitions planned in the Middle East
Mark Saldanha · Chairman and Managing Director · p. 9
Middle East: No acquisitions planned in the Middle East
“There are no M&As or acquisitions planned in the Middle East.”
Dividends and buybacks
Buyback remains an option under evaluation
Mark Saldanha · Chairman and Managing Director · p. 11
Buyback remains an option under evaluation
“Buyback is always an option, and we have discussed this, and we will continue evaluating as and when we feel if nothing else is happening, that could be a possibility also.”
Dividend broadly in line with history of about one third of free cash flow
Jitendra Sharma · Chief Financial Officer · p. 15
Dividend broadly in line with history of about one third of free cash flow
“Historically, like, 1/3 of our free cash flow generation, we have been distributing as dividend. Broadly, it will be in line with that.”
One-offs
Germany: German business incurred startup costs of a couple of crores
Jitendra Sharma · Chief Financial Officer · p. 5
Germany: German business incurred startup costs of a couple of crores
“In addition, our German business incurred initial startup costs of a couple of crores as we prepare these operations for the next phase.”
PAT fell to INR144 crore from INR159 crore in Q1 on higher amortisation
Jitendra Sharma · Chief Financial Officer · p. 5
PAT fell to INR144 crore from INR159 crore in Q1 on higher amortisation
“Profit after tax declined sequentially to INR144 crores compared with INR159 crores in Q1, primarily due to higher depreciation and amortization”
Intangible assets now amortised over 10 years from this quarter
Jitendra Sharma · Chief Financial Officer · p. 13
Intangible assets now amortised over 10 years from this quarter
“From this quarter, we basically are treating intangible assets as having a finite useful life, and we have started depreciating it over a period of 10 years.”
Depreciation rise also from acquired QliniQ and ABCnow intangibles
Jitendra Sharma · Chief Financial Officer · p. 13
Depreciation rise also from acquired QliniQ and ABCnow intangibles
“The reason for the increase in this figure was, we have also started providing for depreciation on acquired intangible assets from QliniQ and ABCnow.”
Risks
U.S.: U.S. prescription price erosion in single digits
Mark Saldanha · Chairman and Managing Director · p. 4
U.S.: U.S. prescription price erosion in single digits
“price erosion in our prescription products, although being in single digits, we are still looking extremely optimistic in the U.S. market.”
Rest of World: Rest of World shipments delayed by Middle East geopolitical disruption
Mark Saldanha · Chairman and Managing Director · p. 4
Rest of World: Rest of World shipments delayed by Middle East geopolitical disruption
“Our Rest of World business remained impacted in the quarter by ongoing geopolitical disruptions in the Middle East and other regions, which affected the timing of certain shipments in the region.”
Rest of World: Rest of World H1 hit by vessels stuck in Red Sea and logistics chaos
Mark Saldanha · Chairman and Managing Director · p. 11
Rest of World: Rest of World H1 hit by vessels stuck in Red Sea and logistics chaos
“The first half was a bit of a struggle because it affected transportation, it affected vessels, which were obviously all stuck in the Red Sea, and everything, there was chaos related to logistics and supply chain.”
Margin upside depends on the war ending
Mark Saldanha · Chairman and Managing Director · Q&A · p. 18
Margin upside depends on the war ending
“There is always a possibility, but for that, you have got to call the president and call off the war.”
Gross margin outlook depends on crude prices and the war
Mark Saldanha · Chairman and Managing Director · p. 15
Gross margin outlook depends on crude prices and the war
“If the crude prices come down, you will see it going down. If the war goes from bad to worse, then obviously, all projections go for a toss.”
Other
Q2 revenue from operations INR940 crore, up 30.5% year on year
Mark Saldanha · Chairman and Managing Director · p. 3
Q2 revenue from operations INR940 crore, up 30.5% year on year
“Q2 was a record quarter for us, with revenue from operations reaching INR940 crores, representing a year-on-year growth of 30.5%.”
Growth excluding QliniQ was about 25%
Mark Saldanha · Chairman and Managing Director · p. 3
Growth excluding QliniQ was about 25%
“Even excluding the contribution from QliniQ, our underlying business delivered a growth of approximately 25%.”
Q2 profit after tax up 44.8% to INR144 crore; net margin 15%
Jitendra Sharma · Chief Financial Officer · p. 5
Q2 profit after tax up 44.8% to INR144 crore; net margin 15%
“Profit after tax increased by 44.8% to INR144 crores, with a net margin of 15%.”
H1 revenue from operations up 32.9% to INR1,781 crore
Jitendra Sharma · Chief Financial Officer · p. 6
H1 revenue from operations up 32.9% to INR1,781 crore
“revenue from operations increased by 32.9% to INR1,781 crores”
H1 profit after tax up 92.5% to INR303 crore
Jitendra Sharma · Chief Financial Officer · p. 6
H1 profit after tax up 92.5% to INR303 crore
“Profit after tax increased by 92.5% to INR303 crores, with a net margin of 16.6%.”
Sources
- Earnings call transcript, Q2 FY27 Filed 13 Nov 2026 · 18 pages
Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

